APO Research
Talk to an analyst

APO RESEARCH · REPORT

Post herpetic Neuralgia Treatment

Post herpetic neuralgia is a painful condition that can occur after having shingles, a complication of chicken pox. The goal of therapy for post herpetic neuralgia is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids and antiviral agents.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Post herpetic neuralgia is a painful condition that can occur after having shingles, a complication of chicken pox. The goal of therapy for post herpetic neuralgia is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids and antiviral agents.

Selected research

Market Outlook & Growth Opportunities

Global Post herpetic Neuralgia Treatment Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchPost herpetic Neuralgia Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Post herpetic Neuralgia Treatment Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Post herpetic Neuralgia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Post herpetic Neuralgia Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Post herpetic Neuralgia Treatment Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Post herpetic neuralgia is a painful condition that can occur after having shingles, a complication of chicken pox. The goal of therapy for post herpetic neuralgia is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids and antiviral agents.

Global Post herpetic Neuralgia Treatment key players include Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, etc. Global top five manufacturers hold a share about 80%.

North America is the largest market, with a share over 50%, followed by Europe and China, both have a share about 30 percent.

Read the full market overview

In terms of product, Anticonvulsants is the largest segment, with a share over 80%. And in terms of distribution channel, the largest distribution channel is Hospital Pharmacies, followed by Retail Pharmacies.

This report provides an overview of the global Post herpetic Neuralgia Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Post herpetic Neuralgia Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Post herpetic Neuralgia Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Post herpetic Neuralgia Treatment market.

Post herpetic Neuralgia Treatment Segment by Company

Pfizer

Arbor Pharma

Assertio Therapeutics

Endo Pharma

Teikoku Pharma

Teva

Mylan

Hengrui Medicine

Post herpetic Neuralgia Treatment Segment by Type

Anticonvulsants

Skin Patch

Other

Post herpetic Neuralgia Treatment Segment by Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Post herpetic Neuralgia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Post herpetic Neuralgia Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Post herpetic Neuralgia Treatment key companies, revenue, market share, and recent developments.

3. To split the Post herpetic Neuralgia Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Post herpetic Neuralgia Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Post herpetic Neuralgia Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Post herpetic Neuralgia Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post herpetic Neuralgia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Post herpetic Neuralgia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post herpetic Neuralgia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Post herpetic Neuralgia Treatment industry.

Chapter 3: Detailed analysis of Post herpetic Neuralgia Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Post herpetic Neuralgia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Post herpetic Neuralgia Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Post herpetic Neuralgia Treatment Industry Trends Table 2. Post herpetic Neuralgia Treatment Industry Drivers Table 3. Post herpetic Neuralgia Treatment Industry Opportunities and Challenges Table 4. Post herpetic Neuralgia Treatment Industry Restraints Table 5. Global Post herpetic Neuralgia Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Post herpetic Neuralgia Treatment Revenue Share by Company (2021-2026) Table 7. Global Post herpetic Neuralgia Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Post herpetic Neuralgia Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Post herpetic Neuralgia Treatment Company, Product Type & Application Table 10. Global Post herpetic Neuralgia Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Post herpetic Neuralgia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anticonvulsants Table 15. Significant Companies of Skin Patch Table 16. Significant Companies of Other Table 17. Global Post herpetic Neuralgia Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Post herpetic Neuralgia Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Post herpetic Neuralgia Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Post herpetic Neuralgia Treatment Sales Value Share by Type (2021-2026) Table 21. Global Post herpetic Neuralgia Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Pharmacies Table 23. Significant Companies of Online Pharmacies Table 24. Significant Companies of Retail Pharmacies Table 25. Global Post herpetic Neuralgia Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Post herpetic Neuralgia Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Post herpetic Neuralgia Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Post herpetic Neuralgia Treatment Sales Value Share by Application (2021-2026) Table 29. Global Post herpetic Neuralgia Treatment Sales Value Share by Application (2027-2032) Table 30. Global Post herpetic Neuralgia Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Post herpetic Neuralgia Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Post herpetic Neuralgia Treatment Sales Value Share by Region (2021-2026) Table 33. Global Post herpetic Neuralgia Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Post herpetic Neuralgia Treatment Sales Value Share by Region (2027-2032) Table 35. Global Post herpetic Neuralgia Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Post herpetic Neuralgia Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Post herpetic Neuralgia Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Post herpetic Neuralgia Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Post herpetic Neuralgia Treatment Sales Value Market Share by Country (2027-2032) Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Pfizer Post herpetic Neuralgia Treatment Product Portfolio Table 44. Pfizer Recent Development Table 45. Arbor Pharma Company Information Table 46. Arbor Pharma Business Overview Table 47. Arbor Pharma Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Arbor Pharma Post herpetic Neuralgia Treatment Product Portfolio Table 49. Arbor Pharma Recent Development Table 50. Assertio Therapeutics Company Information Table 51. Assertio Therapeutics Business Overview Table 52. Assertio Therapeutics Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Assertio Therapeutics Post herpetic Neuralgia Treatment Product Portfolio Table 54. Assertio Therapeutics Recent Development Table 55. Endo Pharma Company Information Table 56. Endo Pharma Business Overview Table 57. Endo Pharma Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Endo Pharma Post herpetic Neuralgia Treatment Product Portfolio Table 59. Endo Pharma Recent Development Table 60. Teikoku Pharma Company Information Table 61. Teikoku Pharma Business Overview Table 62. Teikoku Pharma Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Teikoku Pharma Post herpetic Neuralgia Treatment Product Portfolio Table 64. Teikoku Pharma Recent Development Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Post herpetic Neuralgia Treatment Product Portfolio Table 69. Teva Recent Development Table 70. Mylan Company Information Table 71. Mylan Business Overview Table 72. Mylan Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Mylan Post herpetic Neuralgia Treatment Product Portfolio Table 74. Mylan Recent Development Table 75. Hengrui Medicine Company Information Table 76. Hengrui Medicine Business Overview Table 77. Hengrui Medicine Post herpetic Neuralgia Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Hengrui Medicine Post herpetic Neuralgia Treatment Product Portfolio Table 79. Hengrui Medicine Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Post herpetic Neuralgia Treatment Product Image Figure 2. Global Post herpetic Neuralgia Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Post herpetic Neuralgia Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Post herpetic Neuralgia Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anticonvulsants Image Figure 8. Skin Patch Image Figure 9. Other Image Figure 10. Global Post herpetic Neuralgia Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Post herpetic Neuralgia Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Post herpetic Neuralgia Treatment Sales Value Share by Type (2021-2032) Figure 13. Hospital Pharmacies Image Figure 14. Online Pharmacies Image Figure 15. Retail Pharmacies Image Figure 16. Global Post herpetic Neuralgia Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Post herpetic Neuralgia Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Post herpetic Neuralgia Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Post herpetic Neuralgia Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Post herpetic Neuralgia Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Post herpetic Neuralgia Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Post herpetic Neuralgia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Post herpetic Neuralgia Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Post herpetic Neuralgia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Post herpetic Neuralgia Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Post herpetic Neuralgia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Post herpetic Neuralgia Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Post herpetic Neuralgia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Post herpetic Neuralgia Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Post herpetic Neuralgia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Anticonvulsants
  • Skin Patch
  • Other
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Pfizer
  • Arbor Pharma
  • Assertio Therapeutics
  • Endo Pharma
  • Teikoku Pharma
  • Teva
  • Mylan
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Post herpetic Neuralgia Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Post herpetic Neuralgia Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Post herpetic Neuralgia Treatment Market Dynamics
  1. 2.1 Post herpetic Neuralgia Treatment Industry Trends
  2. 2.2 Post herpetic Neuralgia Treatment Industry Drivers
  3. 2.3 Post herpetic Neuralgia Treatment Industry Opportunities and Challenges
  4. 2.4 Post herpetic Neuralgia Treatment Industry Restraints
3 Post herpetic Neuralgia Treatment Market by Company
  1. 3.1 Global Post herpetic Neuralgia Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Post herpetic Neuralgia Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Post herpetic Neuralgia Treatment Company Ranking (2024-2026)
  4. 3.4 Global Post herpetic Neuralgia Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Post herpetic Neuralgia Treatment Company Product Type and Application
  6. 3.6 Global Post herpetic Neuralgia Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Post herpetic Neuralgia Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Post herpetic Neuralgia Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Post herpetic Neuralgia Treatment Market by Type
  1. 4.1 Post herpetic Neuralgia Treatment Type Introduction
  2. 4.1.1 Anticonvulsants
  3. 4.1.2 Skin Patch
  4. 4.1.3 Other
  5. 4.2 Global Post herpetic Neuralgia Treatment Sales Value by Type
  6. 4.2.1 Global Post herpetic Neuralgia Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Post herpetic Neuralgia Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Post herpetic Neuralgia Treatment Sales Value Share by Type (2021-2032)
5 Post herpetic Neuralgia Treatment Market by Application
  1. 5.1 Post herpetic Neuralgia Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Post herpetic Neuralgia Treatment Sales Value by Application
  6. 5.2.1 Global Post herpetic Neuralgia Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Post herpetic Neuralgia Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Post herpetic Neuralgia Treatment Sales Value Share by Application (2021-2032)
6 Post herpetic Neuralgia Treatment Regional Value Analysis
  1. 6.1 Global Post herpetic Neuralgia Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Post herpetic Neuralgia Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Post herpetic Neuralgia Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Post herpetic Neuralgia Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Post herpetic Neuralgia Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Post herpetic Neuralgia Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Post herpetic Neuralgia Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Post herpetic Neuralgia Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Post herpetic Neuralgia Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Post herpetic Neuralgia Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Post herpetic Neuralgia Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Post herpetic Neuralgia Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Post herpetic Neuralgia Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Post herpetic Neuralgia Treatment Sales Value Share by Country, 2025 VS 2032
7 Post herpetic Neuralgia Treatment Country-level Value Analysis
  1. 7.1 Global Post herpetic Neuralgia Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Post herpetic Neuralgia Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Post herpetic Neuralgia Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Post herpetic Neuralgia Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Post herpetic Neuralgia Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Post herpetic Neuralgia Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Post herpetic Neuralgia Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Post herpetic Neuralgia Treatment Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Arbor Pharma
  8. 8.2.1 Arbor Pharma Company Information
  9. 8.2.2 Arbor Pharma Business Overview
  10. 8.2.3 Arbor Pharma Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Arbor Pharma Post herpetic Neuralgia Treatment Product Portfolio
  12. 8.2.5 Arbor Pharma Recent Developments
  13. 8.3 Assertio Therapeutics
  14. 8.3.1 Assertio Therapeutics Company Information
  15. 8.3.2 Assertio Therapeutics Business Overview
  16. 8.3.3 Assertio Therapeutics Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Assertio Therapeutics Post herpetic Neuralgia Treatment Product Portfolio
  18. 8.3.5 Assertio Therapeutics Recent Developments
  19. 8.4 Endo Pharma
  20. 8.4.1 Endo Pharma Company Information
  21. 8.4.2 Endo Pharma Business Overview
  22. 8.4.3 Endo Pharma Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Endo Pharma Post herpetic Neuralgia Treatment Product Portfolio
  24. 8.4.5 Endo Pharma Recent Developments
  25. 8.5 Teikoku Pharma
  26. 8.5.1 Teikoku Pharma Company Information
  27. 8.5.2 Teikoku Pharma Business Overview
  28. 8.5.3 Teikoku Pharma Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Teikoku Pharma Post herpetic Neuralgia Treatment Product Portfolio
  30. 8.5.5 Teikoku Pharma Recent Developments
  31. 8.6 Teva
  32. 8.6.1 Teva Company Information
  33. 8.6.2 Teva Business Overview
  34. 8.6.3 Teva Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Post herpetic Neuralgia Treatment Product Portfolio
  36. 8.6.5 Teva Recent Developments
  37. 8.7 Mylan
  38. 8.7.1 Mylan Company Information
  39. 8.7.2 Mylan Business Overview
  40. 8.7.3 Mylan Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan Post herpetic Neuralgia Treatment Product Portfolio
  42. 8.7.5 Mylan Recent Developments
  43. 8.8 Hengrui Medicine
  44. 8.8.1 Hengrui Medicine Company Information
  45. 8.8.2 Hengrui Medicine Business Overview
  46. 8.8.3 Hengrui Medicine Post herpetic Neuralgia Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Medicine Post herpetic Neuralgia Treatment Product Portfolio
  48. 8.8.5 Hengrui Medicine Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst